Phase IV ipilimumab in melanoma A National, Multicenter, Interventional Study in Patients with Unresectable or Metastatic Melanoma

Trial Profile

Phase IV ipilimumab in melanoma A National, Multicenter, Interventional Study in Patients with Unresectable or Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2015

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Apr 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2018 as reported by ClinicalTrials.gov.
    • 09 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Nov 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top